VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ASH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ASHAshland Inc.
$65.73$3.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ASH logoAshland Inc.(ASH)Earnings, Financials & Key Ratios

ASH•NYSE
$65.73
Price updated Jul 7, 2026
SectorBasic MaterialsIndustrySpecialty ChemicalsSub-IndustrySpecialty additives and formulation chemicals
AboutAshland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. Ashland Inc. was founded in 1924 and is based in Wilmington, Delaware.Show more
  • Revenue$1.82B-13.7%
  • EBITDA-$538M-316.9%
  • Net Income-$845M-600.0%
  • EPS (Diluted)-18.37-643.5%
  • Gross Margin30.1%+2.9%
  • EBITDA Margin-29.5%-351.3%
  • Operating Margin-42.49%-3353.0%
  • Net Margin-46.33%-679.2%
  • ROE-35.41%-725.0%

ASH Price & Volume

Ashland Inc. (ASH) stock price & volume — 10-year historical chart

Loading chart...

Legacy Liabilities Obscure Specialty Chemical Portfolio Transition

Investment Thesis • Updated 2026Q2

VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Legacy liability impairment volatility

Key Thesis Takeaways

  • Ashland is currently navigating a complex strategic pivot toward specialty ingredients, though the transition remains hampered by significant earnings volatility and non-recurring charges, such as the $742 million net loss recorded in 2025Q3.
  • While the company maintains a robust liquidity position with a 3.06 current ratio, investors should monitor the sustainability of its capital allocation strategy given the erratic nature of free cash flow margins, which have fluctuated between -15.6% and 31.9%.
  • The long-term outlook depends on management's ability to stabilize top-line growth, which showed only a marginal 0.6% year-over-year increase in 2026Q2, while simultaneously mitigating the impact of legacy environmental liabilities on bottom-line profitability.

Verdict Logic

while the company maintains a healthy 3.06 current ratio, the extreme volatility in earnings and the $742 million net loss in 2025Q3 suggest that the underlying business transition has yet to achieve the stability required for a clear buy recommendation.

ASH Growth Metrics

Ashland Inc. (ASH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-6.09%
5 Years-1.98%
3 Years-8.63%
TTM-7.23%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-530.36%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-539.17%

Return on Capital

10 Years-0.95%
5 Years-0.97%
3 Years-4.66%
Last Year-16.59%

ASH Recent Earnings

Ashland Inc. (ASH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Apr 28, 2026
Metric
Actual
Est
EPS
$0.91-6.2%
$0.97
Rev
$482M-0.7%
$486M
Q1 2026
Feb 2, 2026
Metric
Actual
Est
EPS
$0.26+13.0%
$0.23
Rev
$386M-3.7%
$401M
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$1.08-7.7%
$1.17
Rev
$478M+20.4%
$397M
Q3 2025
Jul 29, 2025
Metric
Actual
Est
EPS
$1.04-9.6%
$1.15
Rev
$463M-4.1%
$483M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 28, 2026
$0.91vs $0.97-6.2%
$482Mvs $486M-0.7%
Q1 2026Feb 2, 2026
$0.26vs $0.23+13.0%
$386Mvs $401M-3.7%
Q4 2025Nov 4, 2025
$1.08vs $1.17-7.7%
$478Mvs $397M+20.4%
Q3 2025Jul 29, 2025
$1.04vs $1.15-9.6%
$463Mvs $483M-4.1%
Based on last 12 quarters of dataView full earnings history →

Latest ASH News

Recent stock market news and headlines for Ashland Inc. (ASH)

GuruFocus·Jun 26, 2026
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

Peers Comparison

Key metrics vs top competitors for Ashland Inc. (ASH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ASH logoASHAshland Inc.Current
$65.73$3.01B-3.58-13.68%-46.33%-35.41%2.51%
RPM logoRPMRPM International Inc.
$108.28$13.87B20.240.51%8.63%21.79%—
IFF logoIFFInternational Flavors & Fragrances Inc.
$81.83$20.9B-56.05-5.17%7.78%5.88%—
FUL logoFULH.B. Fuller Company
$57.57$3.1B20.93-2.67%5.29%9.16%—
AVNT logoAVNTAvient Corporation
$38.10$3.49B42.810.61%4.81%6.6%—
BCPC logoBCPCBalchem Corporation
$168.11$5.38B35.398.75%14.95%12.38%—

Compare ASH vs Peers

Ashland Inc. (ASH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RPM

Most directly comparable listed peer for ASH.

Scale Benchmark

vs SHW

Larger-name benchmark to compare ASH against a more recognizable public peer.

Peer Set

Compare Top 5

vs RPM, IFF, FUL, AVNT

ASH SEC Filings & Documents

Ashland Inc. (ASH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 28, 2026·SEC

Material company update

Feb 2, 2026·SEC

Material company update

Jan 27, 2026·SEC

10-K Annual Reports

2
FY 2025

Nov 20, 2025·SEC

FY 2024

Nov 18, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 29, 2026·SEC

FY 2026

Feb 3, 2026·SEC

FY 2025

Jul 30, 2025·SEC

Get notified when ASH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ASH Frequently Asked Questions

Ashland Inc. (ASH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Ashland Inc.'s revenue?

Ashland Inc. (ASH) reported $1.81B in revenue for fiscal year 2025. This represents a 84% decrease from $11.33B in 1996.

How fast is Ashland Inc. growing?

Ashland Inc. (ASH) saw revenue decline by 13.7% over the past year.

Is ASH profitable?

Ashland Inc. (ASH) reported a net loss of $706.0M for fiscal year 2025.

Dividend & Returns
Does ASH pay dividends?

Yes, Ashland Inc. (ASH) pays a dividend with a yield of 2.51%. This makes it attractive for income-focused investors.

What is ASH's return on equity?

Ashland Inc. (ASH) has a return on equity (ROE) of -35.4%. Negative ROE indicates the company is unprofitable.

What is Ashland Inc.'s free cash flow?

Ashland Inc. (ASH) generated $343.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ASH back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →